儿童急性淋巴细胞白血病合并血栓与生存期缩短相关:CYP-C报告
该研究基于加拿大CYP-C登记库,纳入2000-2016年诊断的2006例<15岁新发ALL患儿,评估治疗期间影像学确认需医疗干预的血栓栓塞对生存的影响。血栓栓塞发生率为5.6%,中位发生时间为诊断后107天。多因素Cox回归显示,血栓栓塞与更差的总生存(aHR 2.61)和无事件生存(aHR 2.03)显著相关,且该关联主要见于高危/极高危组。
要点
- 儿童ALL治疗期间血栓栓塞发生率5.6%,中位发生于诊断后107天。
- 合并血栓栓塞者总生存(aHR 2.61)和无事件生存(aHR 2.03)显著更差。
- 血栓栓塞对生存的不良影响主要见于高危/极高危ALL患儿。
核心结论
- 儿童ALL治疗期间发生血栓栓塞与更差的总生存和无事件生存显著相关。
- 血栓栓塞对生存的不良影响主要见于高危/极高危ALL患儿,标准/低危组未见统计学显著差异。
研究设计与样本
- 基于加拿大CYP-C登记库的群体回顾性队列研究,纳入2000-2016年诊断的2006例<15岁新发ALL患儿。
- 主要暴露变量为需医疗干预的影像学确认血栓栓塞,采用多因素Cox回归(血栓栓塞为时变变量)分析对生存的影响。
主要发现
- 2006例患儿中位年龄4岁,88.5%为前体B细胞ALL。
- 113例(5.6%)发生血栓栓塞,中位发生时间为诊断后107天(IQR 35-184天)。
- 标准/低危组血栓栓塞发生率3.5%(41/1165),高危/极高危组8.6%(72/841)。
- 合并血栓栓塞者总生存aHR 2.61(95%CI 1.62-4.22,p<0.001),无事件生存aHR 2.03(95%CI 1.35-3.05,p=0.001)。
- 高危/极高危组中,血栓栓塞与更差总生存(aHR 2.90,95%CI 1.79-4.72,p<0.001)和无事件生存(aHR 2.02,95%CI 1.30-3.12,p=0.002)相关。
临床怎么用
- 在高危/极高危ALL患儿中,应将血栓栓塞视为不良预后标志,加强监测与预防管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There are conflicting data about whether the development of cancer-associated thrombo-embolism (TE) negatively impacts survival in children. The objective was to determine whether TE during treatment was associated with overall survival (OS) and event-free survival (EFS) in children with acute lymphoblastic leukemia (ALL). We performed a population-based retrospective cohort study using the Cancer in Young People-Canada registry. Children <15 years of age were diagnosed with de novo ALL (2000-2016). The primary exposure variable was radiologically-confirmed thrombo-embolism requiring medical intervention. Multivariable Cox regression models were used to determine the impact of thrombo-embolism on survival, where TE was time-dependent. We included 2006 children (median age: 4 years, 88.5% precursor B-cell ALL). Thrombo-embolism occurred in 113 patients (5.6%), at a median time of 107 days (interquartile range: 35-184 days) after ALL diagnosis. Among standard/low-risk patients, 41/1165 (3.5%) developed TE while among high/very high-risk patients, 72/841 (8.6%) developed TE. Patients with TE had a significantly worse OS (adjusted HR [aHR] of death: 2.61, 95% CI: 1.62-4.22, p < 0.001) and EFS (aHR of an event [death, relapse, second malignancy]: 2.03, 95% CI: 1.35-3.05, p = 0.001), compared with patients without TE. No statistically significant difference was seen in standard/low risk ALL for OS and EFS, but TE was associated with a significantly lower OS and EFS in children with high/very high-risk ALL (aHR of death: 2.90, 95% CI: 1.79-4.72, p < 0.001; aHR of an event: 2.02, 95% CI: 1.30-3.12, p = 0.002). Thus, TE led to a statistically significant reduction in OS and EFS in children with high risk/very high-risk leukemia.
引用
- Pelland-Marcotte MC, Kulkarni K, Athale UH, et al. Thrombosis is associated with worse survival in children with acute lymphoblastic leukemia: A report from CYP-C. Am J Hematol. 2021. PMID: 33848369. doi:10.1002/ajh.26193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。